Aethlon Medical, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, specializing in the development of medical devices designed to address serious health threats caused by pathogens and disease-associated toxins. The company’s core focus is on extracorporeal filtration technologies that target and remove harmful biological agents directly from the bloodstream. Aethlon’s platform is intended to complement existing therapeutic approaches by enhancing the body’s ability to clear infectious agents and tumor-derived factors that contribute to disease progression.
The company’s lead product candidate, the Aethlon Hemopurifier, is a patented blood filtration device engineered to selectively bind and remove enveloped viruses and immunosuppressive exosomes. Constructed using an affinity-based sorbent matrix, the Hemopurifier is designed for use in conjunction with standard dialysis and hemofiltration equipment. Ongoing clinical programs have explored its application in treating severe viral infections, including hepatitis C, Ebola, and COVID-19, as well as its potential to support oncology patients by clearing tumor-derived exosomes that can inhibit immune response.
Founded in the early 2000s, Aethlon Medical has pursued a strategy of advancing its pipeline through collaboration with leading academic research institutions and medical centers across North America. The company’s research and development efforts are bolstered by partnerships with virology laboratories and contract research organizations in the United States and Europe. Aethlon’s work adheres to stringent regulatory standards set by the U.S. Food and Drug Administration, and the company has completed multiple preclinical studies and early-phase human trials to evaluate the safety and efficacy of its Hemopurifier in diverse patient populations.
Under the leadership of President and Chief Executive Officer Roy H. Bickell, Aethlon Medical’s executive team and board of directors bring extensive experience in medical device development, regulatory affairs, and global commercialization. The company continues to refine its filtration technology and expand its clinical trial initiatives with a view to achieving broader regulatory milestones and preparing for potential market entry. Aethlon remains committed to addressing unmet medical needs by delivering innovative therapies that enhance patient outcomes in the face of emerging and persistent health challenges.
AI Generated. May Contain Errors.
Free AEMD Stock Alerts